

Anna L Zignego

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488016/publications.pdf>

Version: 2024-02-01

187
papers

9,293
citations

34105

52
h-index

45317

90
g-index

189
all docs

189
docs citations

189
times ranked

5459
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , 2022, 41, 147-157.	2.2	4
2	Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , 2022, 21, 102923.	5.8	10
3	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 441-443.	0.9	12
4	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	7.3	12
5	Reply. <i>Hepatology</i> , 2022, 76, E11-E12.	7.3	0
6	B cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma. <i>Hematological Oncology</i> , 2022, , .	1.7	4
7	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BAiT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	1.6	8
8	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
9	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab Biosimilar). <i>Internal and Emergency Medicine</i> , 2021, 16, 149-156.	2.0	8
10	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.9	6
11	<i>PCD1</i> and <i>IFNL4</i> genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , 2021, 41, 133-149.	3.9	3
12	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427.	1.9	4
13	Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome. <i>Minerva Gastroenterology</i> , 2021, 67, 218-226.	0.5	4
14	REPLY:. <i>Hepatology</i> , 2021, 74, 2910-2910.	7.3	1
15	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032.	3.3	19
16	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. <i>Hepatology</i> , 2021, 74, 1164-1173.	7.3	10
17	Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 2564.	2.4	3
18	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Role of Notch Receptors in Hematologic Malignancies. <i>Cells</i> , 2021, 10, 16.	4.1	9
20	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patientsâ€™ subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	6.5	83
21	SARS-CoV-2 was already circulating in Italy, in early December 2019. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 3342-3349.	0.7	3
22	Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. <i>Current Medical Research and Opinion</i> , 2020, 36, 245-249.	1.9	13
23	Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. <i>Journal of Immunological Methods</i> , 2020, 476, 112687.	1.4	9
24	The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis. <i>Viruses</i> , 2020, 12, 1364.	3.3	5
25	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. <i>Genes and Immunity</i> , 2020, 21, 131-135.	4.1	11
26	Fibrosis Assessment in Patients with HCV or HBV Chronic Infection. , 2020, , 113-121.		0
27	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019, 35, 661-666.	1.9	3
28	Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. <i>Liver International</i> , 2019, 39, 628-632.	3.9	31
29	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	4.4	8
30	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019, 47, 141-168.	4.7	0
31	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.	2.0	24
32	Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. <i>Digestive and Liver Disease</i> , 2018, 50, 938-943.	0.9	10
33	Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated <sc>HCV</sc>-related condition in the real life practice. <i>Liver International</i> , 2018, 38, 183-183.	3.9	5
34	Current and future challenges in HCV: insights from an Italian experts panel. <i>Infection</i> , 2018, 46, 147-163.	4.7	4
35	Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis. <i>Antiviral Therapy</i> , 2018, 23, 1-9.	1.0	10
36	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018, 13, 1139-1166.	2.0	2

#	ARTICLE	IF	CITATIONS
37	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018, 31, 685-712.	2.0	3
38	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018, 50, 1133-1152.	0.9	5
39	Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. <i>Clinical and Experimental Hepatology</i> , 2018, 4, 197-200.	1.3	8
40	Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemia—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 772-773.	3.7	0
41	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
42	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	30.5	143
43	Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 440-450.	3.7	28
44	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
45	Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. <i>Acta Biomedica</i> , 2018, 89, 321-331.	0.3	9
46	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
47	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19
48	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , 2017, 806, 105-109.	3.5	24
49	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
50	Reply. <i>Hepatology</i> , 2017, 65, 1771-1772.	7.3	10
51	Free light chains: Eclectic multipurpose biomarker. <i>Journal of Immunological Methods</i> , 2017, 451, 11-19.	1.4	33
52	IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. <i>Digestive and Liver Disease</i> , 2017, 49, 1233-1239.	0.9	17
53	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	7.3	25
54	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15

#	ARTICLE	IF	CITATIONS
55	Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. <i>Arthritis Research and Therapy</i> , 2017, 19, 44.	3.5	9
56	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	2.5	42
57	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
58	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. <i>Oncotarget</i> , 2017, 8, 71528-71535.	1.8	11
59	Treatment of HCV-Related Mixed Cryoglobulinemia. <i>Current Drug Targets</i> , 2017, 18, 794-802.	2.1	18
60	HCV-Related Rheumatic Manifestations and Therapeutic Strategies. <i>Current Drug Targets</i> , 2017, 18, 803-810.	2.1	8
61	Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study. <i>Current Drug Targets</i> , 2017, 18, 772-785.	2.1	47
62	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie "GISC. <i>Digestive and Liver Disease</i> , 2016, 48, 780-784.	0.9	50
63	A randomized, controlled study of peginterferon lambda-1a/ribavirin±A±A±daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
64	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016, 64, 1473-1482.	7.3	167
65	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87
66	Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. <i>Digestive and Liver Disease</i> , 2016, 48, 927-933.	0.9	14
67	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.9	13
68	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. <i>Oncotarget</i> , 2016, 7, 37487-37497.	1.8	16
69	Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. <i>BMJ, The</i> , 2015, 350, h3363-h3363.	6.0	5
70	Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , 2015, 35, 2100-2107.	3.9	17
71	MicroRNA expression in hepatitis C virus-related malignancies: A brief review. <i>World Journal of Gastroenterology</i> , 2015, 21, 8562.	3.3	14
72	HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. <i>World Journal of Hepatology</i> , 2015, 7, 327.	2.0	118

#	ARTICLE	IF	CITATIONS
73	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015, 14, 889-896.	5.8	53
74	Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials. <i>Digestive and Liver Disease</i> , 2015, 47, 988-989.	0.9	0
75	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-31.	3.0	73
76	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. <i>Journal of Autoimmunity</i> , 2015, 63, 88-93.	6.5	41
77	Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5.	0.4	28
78	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. <i>PLoS ONE</i> , 2015, 10, e0117420.	2.5	54
79	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , 2015, 9, 586-593.	4.2	7
80	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	7.3	107
81	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 3013.	3.3	12
82	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	16
83	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014, 46, S165-S173.	0.9	218
84	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 21.	4.4	14
85	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.	4.1	55
86	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.9	57
87	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	1.9	67
88	Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. <i>Clinical Rheumatology</i> , 2013, 32, 1147-1154.	2.2	13
89	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 840-843.	0.9	47
90	Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. <i>Journal of Hepatology</i> , 2013, 59, 1362-1363.	3.7	8

#	ARTICLE	IF	CITATIONS
91	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. PLoS ONE, 2013, 8, e62965.	2.5	42
92	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. Journal of Viral Hepatitis, 2013, 20, e107-14.	2.0	16
93	High Circulating Chemokines (C-X-C Motif) Ligand 9, and (C-X-C Motif) Ligand 11, in Hepatitis C-Associated Cryoglobulinemia. International Journal of Immunopathology and Pharmacology, 2013, 26, 49-57.	2.1	6
94	Hepatitis C virus-related mixed cryoglobulinemia: Is genetics to blame?. World Journal of Gastroenterology, 2013, 19, 8910.	3.3	20
95	HCV and Lymphoproliferation. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	84
96	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. Journal of Translational Medicine, 2012, 10, 158.	4.4	14
97	The hepatitis C virus infection as a systemic disease. Internal and Emergency Medicine, 2012, 7, 201-208.	2.0	42
98	The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia. , 2012, , 155-162.		3
99	A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and Rheumatism, 2012, 64, 843-853.	6.7	337
100	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clinical and Experimental Rheumatology, 2012, 30, S48-52.	0.8	25
101	Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 1183-1190.	0.9	121
102	The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis. Journal of Viral Hepatitis, 2011, 18, 525-532.	2.0	14
103	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews, 2011, 10, 444-454.	5.8	186
104	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmunity Reviews, 2011, 10, 714-719.	5.8	64
105	Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. Autoimmunity Reviews, 2011, 11, 48-55.	5.8	158
106	Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fcγ3 receptors. Arthritis and Rheumatism, 2011, 63, 1446-1451.	6.7	59
107	Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clinical and Experimental Rheumatology, 2011, 29, 933-41.	0.8	32
108	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood, 2010, 116, 335-342.	1.4	112

#	ARTICLE	IF	CITATIONS
109	Hepatitis C virus RNA localization in human carotid plaques. <i>Journal of Clinical Virology</i> , 2010, 47, 72-75.	3.1	127
110	Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool?. <i>Digestive and Liver Disease</i> , 2009, 41, 863-866.	0.9	31
111	Involvement of PI3K in HCV-related lymphoproliferative disorders. <i>Journal of Cellular Physiology</i> , 2008, 214, 396-404.	4.1	17
112	HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008, 8, 107-111.	5.8	32
113	Extrahepatic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2008, 12, 611-636.	2.1	75
114	Hepatitis C virus (HCV) infection: A systemic disease. <i>Molecular Aspects of Medicine</i> , 2008, 29, 85-95.	6.4	80
115	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. <i>Journal of Hepatology</i> , 2008, 49, 170-174.	3.7	31
116	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	1.4	24
117	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , 2008, 112, 4353-4354.	1.4	25
118	Hepatitis C virus lymphotropism: lessons from a decade of studies. <i>Digestive and Liver Disease</i> , 2007, 39, S38-S45.	0.9	75
119	HCV-related autoimmune and neoplastic disorders: the HCV syndrome. <i>Digestive and Liver Disease</i> , 2007, 39, S13-S21.	0.9	92
120	HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. <i>Digestive and Liver Disease</i> , 2007, 39, S55-S60.	0.9	63
121	Hepatitis C virus core protein enhances B lymphocyte proliferation. <i>Digestive and Liver Disease</i> , 2007, 39, S72-S75.	0.9	14
122	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007, 39, S76-S82.	0.9	10
123	HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. <i>Digestive and Liver Disease</i> , 2007, 39, S107-S111.	0.9	30
124	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.9	18
125	Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. <i>Digestive and Liver Disease</i> , 2007, 39, 2-17.	0.9	222
126	Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 22-28.	2.0	9

#	ARTICLE	IF	CITATIONS
127	B-cells and mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2007, 7, 114-120.	5.8	61
128	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	3.8	19
129	Hepatitis C virus-related lymphoproliferative disorders: An overview. <i>World Journal of Gastroenterology</i> , 2007, 13, 2467.	3.3	109
130	Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 402-408.	2.0	64
131	Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. <i>Hepatology</i> , 2006, 43, 1166-1167.	7.3	35
132	Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. <i>Oncology Reports</i> , 2006, 15, 1305-8.	2.6	16
133	JH6 Gene Usage among HCV-Associated MALT Lymphomas Harboring t(14;18) Translocation. <i>Journal of Immunology</i> , 2005, 174, 3839.1-3839.	0.8	7
134	Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. <i>Cancer Biology and Therapy</i> , 2005, 4, 1192-1194.	3.4	27
135	Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 355-374.	3.4	449
136	Enhanced TH1 cytokine production in hepatitis C virus-infected patients with mixed cryoglobulinemia: understanding the pathological issues. <i>Journal of Hepatology</i> , 2004, 41, 1045-1049.	3.7	12
137	HCV infection, malignancy, and liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1032-1033.	0.6	3
138	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	1.4	99
139	HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S78-84.	0.8	26
140	Prevalence of <i>bcl-2</i> Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. <i>Annals of Internal Medicine</i> , 2002, 137, 571.	3.9	185
141	Erectile Dysfunction and Hepatitis C Virus Infection. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 698-699.	7.4	55
142	Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. <i>Journal of General Virology</i> , 2002, 83, 1665-1671.	2.9	18
143	Cryoglobulins. <i>Journal of Clinical Pathology</i> , 2002, 55, 4-13.	2.0	274
144	Thyroid cancer in HCV-related mixed cryoglobulinemia patients. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, 693-6.	0.8	37

#	ARTICLE	IF	CITATIONS
145	Relation between infection and autoimmunity in mixed cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2000, 12, 53-60.	4.3	73
146	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	7.3	157
147	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. <i>Translational Research</i> , 1999, 134, 68-73.	2.3	47
148	Extrahepatic manifestations of HCV infection: facts and controversies. <i>Journal of Hepatology</i> , 1999, 31, 369-376.	3.7	140
149	Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. <i>Hepatology</i> , 1998, 28, 211-218.	7.3	91
150	Prevalence of Monoclonal Gammopathies in Patients with Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 1998, 129, 294.	3.9	105
151	Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. <i>Lupus</i> , 1998, 7, 275-279.	1.6	90
152	Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. <i>British Journal of Rheumatology</i> , 1997, 36, 360-365.	2.3	72
153	Lymphotropic Virus Infection of Peripheral Blood Mononuclear Cells in B-Cell Non-Hodgkin's Lymphoma. <i>Acta Haematologica</i> , 1997, 98, 89-94.	1.4	14
154	Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. <i>Archives of Virology</i> , 1997, 142, 535-544.	2.1	43
155	Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. <i>Archives of Virology</i> , 1997, 142, 545-555.	2.1	100
156	Correspondence. <i>British Journal of Haematology</i> , 1997, 98, 778-782.	2.5	20
157	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997, 51, 313-318.	5.0	63
158	Hepatitis-C virus infection and cancer. , 1997, 71, 1113-1115.		15
159	Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection. <i>Blood</i> , 1997, 89, 3066-8.	1.4	3
160	Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. <i>Clinical and Experimental Rheumatology</i> , 1997, 15, 711-2.	0.8	22
161	Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 1996, 39, 1074-1075.	6.7	36
162	Hepatitis C Virus Genotype Analysis in Patients with Type II Mixed Cryoglobulinemia. <i>Annals of Internal Medicine</i> , 1996, 124, 31.	3.9	153

#	ARTICLE	IF	CITATIONS
163	Chronic hepatitis C and B-cell non-Hodgkin's lymphoma. QJM - Monthly Journal of the Association of Physicians, 1996, 89, 117-122.	0.5	30
164	Hepatitis C Virus Lymphtropism and Possible Pathogenetic Implications.. , 1996, , 251-259.		0
165	Monoclonal gammopathy in patients with chronic hepatitis C virus infection. Blood, 1996, 88, 1122.	1.4	9
166	Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. Journal of Rheumatology, 1996, 23, 1641-3.	2.0	38
167	Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. Journal of Medical Virology, 1995, 47, 58-64.	5.0	84
168	Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis and Rheumatism, 1995, 38, 1859-1860.	6.7	53
169	Can type C hepatitis infection be complicated by malignant lymphoma?. Lancet, The, 1995, 346, 1426-1427.	13.7	89
170	Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clinical and Experimental Rheumatology, 1995, 13 Suppl 13, S33-7.	0.8	6
171	Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Clinical and Experimental Rheumatology, 1995, 13 Suppl 13, S135-40.	0.8	9
172	Hepatitis C Virus and Mixed Cryoglobulinaemia. Rheumatology, 1994, 33, 301-301.	1.9	6
173	Non-Hodgkin's Lymphoma: Possible Role of Hepatitis C Virus. JAMA - Journal of the American Medical Association, 1994, 272, 355.	7.4	44
174	â€œInapparentâ€ hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. Hepatology, 1994, 19, 577-582.	7.3	44
175	Hepatitis C virus infection in patients with nonâ€Hodgkin's lymphoma. British Journal of Haematology, 1994, 88, 392-394.	2.5	455
176	Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia. European Journal of Clinical Investigation, 1994, 24, 781-784.	3.4	85
177	Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. Journal of Internal Medicine, 1994, 236, 31-36.	6.0	47
178	Hepatitis C virus infection and B-cell lymphomas. European Journal of Cancer, 1994, 30, 1591-1592.	2.8	34
179	Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma. Clinical and Experimental Rheumatology, 1994, 12, 89-90.	0.8	11
180	Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. European Journal of Clinical Investigation, 1993, 23, 851-855.	3.4	80

#	ARTICLE	IF	CITATIONS
181	Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. <i>Infection</i> , 1993, 21, 93-97.	4.7	31
182	Cryoglobulinemia Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus. <i>American Journal of Nephrology</i> , 1993, 13, 300-304.	3.1	58
183	Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. <i>Blood</i> , 1993, 82, 3701-4.	1.4	67
184	Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. <i>Blood</i> , 1993, 81, 1132-6.	1.4	46
185	Infection of peripheral mononuclear blood cells by hepatitis C virus. <i>Journal of Hepatology</i> , 1992, 15, 382-386.	3.7	418
186	Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. <i>Clinical and Experimental Rheumatology</i> , 1991, 9, 23-8.	0.8	7
187	Hepatitis C Virus, B-Cell Disorders, and Non-Hodgkin's Lymphoma. , 0, , 349-368.		19